• Griseofulvin in Microtubule Mechanism Assays

  2026-08-31

  Griseofulvin combines practical antifungal utility with a tractable microtubule mechanism for cell-based phenotyping and mechanistic toxicology. This guide shows how to build dose–response, flow-cytometry, and orthogonal imaging workflows while avoiding common solubility, vehicle, and interpretation errors.

• 7ACC2 for Reliable Cancer Metabolism Assays

  2026-08-31

  Learn how 7ACC2 (SKU B4868) can improve interpretation of lactate transport, mitochondrial pyruvate, proliferation, and cytotoxicity experiments. This scenario-driven guide separates validated product data from workflow recommendations and highlights controls for reproducible cancer metabolism research.

• PDHA1 Succinylation Drives α-KGA Immune Escape

  2026-08-30

  A 2025 Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic control point in cholangiocarcinoma. The modification increases alpha-ketoglutarate accumulation, activates OXGR1–MAPK signaling in macrophages, suppresses MHC-II antigen presentation, and provides a preclinical rationale for combining succinylation-directed intervention with gemcitabine and cisplatin.

• Butylated Hydroxyanisole (BHA) Experimental Workflows

  2026-08-29

  Use BHA as a controllable redox variable rather than a generic additive: pair fresh solvent-based stocks with ROS, viability, and pathway-resolved readouts. This guide translates antioxidant handling into practical workflows for oxidative stress research, apoptosis signaling pathway modulation, and inflammation research while using peptide pharmacology as a model for orthogonal validation.

• Sildenafil Citrate for Native Signaling Research

  2026-08-28

  Sildenafil Citrate combines potent PDE5 inhibition with practical utility in cGMP, vascular, and ERK signaling workflows. This guide translates its use from cell-based assays and smooth-muscle studies into proteoform-aware experiments inspired by native membrane mass spectrometry.

• Syringin N1347: Reliable Cell Assay Workflows

  2026-08-28

  This scenario-driven guide explains how Syringin SKU N1347 can improve reproducibility in cell viability, proliferation, cytotoxicity, and apoptosis workflows. It connects solubility control, assay design, dose-response interpretation, and supplier selection with current evidence on EGFR/PI3K/Akt signaling in renal cell carcinoma.

• DAPT (GSI-IX) in Organoid Signaling Workflows

  2026-08-28

  DAPT (GSI-IX) provides a practical way to perturb γ-secretase-dependent Notch and APP processing in stage-defined cell and organoid models. This guide connects hepatobiliary organoid differentiation with Alzheimer’s disease research, cancer research, and pathway-focused assay design.

• Lysosomal Exocytosis in MPS IVA Cartilage

  2026-08-27

  A 2026 Disease Models & Mechanisms study links GALNS deficiency in zebrafish cartilage to enhanced lysosomal exocytosis, reduced cathepsin activity, altered glycosaminoglycan distribution, and weakened TGFβ/BMP signaling. The findings show that lysosomal exocytosis can contribute to skeletal pathology through mechanisms that differ between lysosomal storage disorders, providing a framework for disease-oriented trafficking and secretion assays.

• Palonosetron for Preventing Chemotherapy-Induced Nausea

  2026-08-26

  Ruhlmann and Herrstedt review why palonosetron may differ from earlier 5-HT3 receptor antagonists, emphasizing its long half-life, high receptor affinity, allosteric binding, and positive cooperativity. The paper shows how these pharmacologic properties may improve protection against delayed chemotherapy-induced nausea and vomiting, while also highlighting the limits of cross-trial comparisons and the continuing importance of combination antiemetic therapy.

• Berberine–Evodiamine Mechanisms in GERD

  2026-08-26

  This 2024 Phytomedicine study identifies TAS2R38 and TRPV1 as a mechanistic interface through which berberine and evodiamine reduce reflux-associated epithelial injury, inflammatory signaling, and macrophage imbalance. By combining a rat GERD model with bile acid-stimulated human esophageal epithelial cells, the work connects receptor activation to MAPK/NF-κB regulation and epithelial barrier preservation.

• STING–CD40–TRAF2 Axis in ESCC B Cells

  2026-08-26

  A 2025 study identifies tertiary lymphoid structures as favorable prognostic features in treatment-naïve esophageal squamous cell carcinoma and defines an STING–CD40–TRAF2–IRF4 mechanism underlying B-cell activation. Its integrated transcriptomic, single-cell, and in vitro approach provides a mechanistic framework for studying TLS biology and evaluating future STING-directed workflows.

• Dimetridazole in Reproducible Microbial Assays

  2026-08-25

  Learn how Dimetridazole, SKU BA1077, can clarify antimicrobial effects in bacterial culture assays, infection model research, and analytical workflows. This scenario-based guide covers controls, stock preparation, concentration selection, electrochemical verification, and practical vendor evaluation.

• ATRNL1 and Cell States in Atrial Fibrillation

  2026-08-24

  A large-scale single-nucleus RNA-sequencing study of human left atrial tissue identifies cardiomyocyte- and macrophage-specific transcriptional changes associated with atrial fibrillation. Functional perturbation of ATRNL1 in human stem cell-derived cardiomyocytes links this previously underexplored gene to cellular stress responses and cardiac action-potential regulation, while also highlighting the importance of cell-type-resolved analysis.

• CLEC5A and ISG20 in Atherosclerosis: Study Insights

  2026-08-24

  Zhang et al. integrate GEO expression data, eQTL evidence, Mendelian randomization, and disease-model validation to investigate genetically supported drivers of atherosclerosis. The study prioritizes CLEC5A and ISG20, with ISG20 showing consistent elevation in ox-LDL-stimulated macrophages and ApoE−/− atherosclerotic lesions, providing a mechanistic hypothesis for macrophage lipid accumulation and inflammation.

• Berberrubine and the Gut–Liver Axis in NAFLD

  2026-08-23

  A 2022 Frontiers in Pharmacology study examined berberrubine, a major berberine metabolite, as an active mediator of protection against diet- and fatty-acid-associated metabolic liver injury. Its comparative mouse, HepG2-cell, protein-expression, and 16S rRNA sequencing data connect improved steatosis and insulin resistance with altered glucose and lipid metabolism and remodeling of gut microbial communities.

450 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page